BBNX
Beta Bionics, Inc.
NASDAQ · Healthcare · Medical - Equipment & Services · US
$19.42
−2.51%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 119.0M | 100.3M | 65.1M | 12.0M | 179.0K |
| Cost of Revenue | 49.6M | 44.7M | 29.2M | 5.7M | — |
| Gross Profit | 69.4M | 55.5M | 35.9M | 6.3M | 179.0K |
| Operating Expenses | |||||
| R&D Expense | 38.9M | 34.8M | 26.2M | 17.9M | 31.4M |
| SG&A Expense | 113.5M | 92.4M | 55.0M | 24.2M | 33.5M |
| General & Admin Expense | 35.7M | 31.0M | 17.9M | 12.2M | 24.7M |
| Selling & Marketing Expense | 77.8M | 61.4M | 37.1M | 12.0M | 8.8M |
| Other Expenses | — | — | — | — | 1.1M |
| Total Operating Expenses | 152.4M | 127.2M | 81.1M | 42.2M | 66.0M |
| Cost and Expenses | 202.0M | 171.9M | 110.4M | 47.8M | 66.0M |
| Operating Income (EBIT) | (83.0M) | (71.7M) | (45.3M) | (35.9M) | (65.8M) |
| Non-Operating | |||||
| Interest Income | 10.0M | 10.9M | 3.9M | 1.8M | 196.0K |
| Interest Expense | — | — | — | — | 14.0K |
| Net Interest Income | 10.0M | 10.9M | 3.9M | 1.8M | 182.0K |
| Other Non-Op Income/Expense | 10.0M | (1.5M) | (9.5M) | (8.2M) | 1.1M |
| Non-Operating Income (excl Interest) | (7.9M) | 1.5M | 9.5M | 8.2M | (1.1M) |
| EBT (Pre-Tax Income) | (73.0M) | (73.2M) | (54.8M) | (44.1M) | (64.8M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (73.0M) | (73.2M) | (54.8M) | (44.1M) | (64.8M) |
| Earnings from Cont. Ops | (73.0M) | (73.2M) | (54.8M) | (44.1M) | (64.8M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (73.0M) | (73.2M) | (54.8M) | (44.1M) | (64.8M) |
| Per Share | |||||
| Basic EPS | ($1.68) | ($1.81) | ($1.28) | ($1.03) | ($1.51) |
| Diluted EPS | ($1.68) | ($1.81) | ($1.28) | ($1.03) | ($1.51) |
| Revenue Per Share | $2.67 | $2.47 | $1.52 | $0.28 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 44.5M | 40.5M | 42.9M | 42.9M | 42.9M |
| Diluted Shares Outstanding | 44.5M | 40.5M | 42.9M | 42.9M | 42.9M |
| Profitability Metrics | |||||
| EBITDA | (71.7M) | (70.3M) | (53.6M) | (42.9M) | (63.4M) |
| D&A | 3.4M | 2.9M | 1.2M | 1.2M | 1.3M |
| EBIT | (75.1M) | (73.2M) | (54.8M) | (44.1M) | (64.7M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026